Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO044 in Duchenne muscular dystrophy
NCT02329769Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Countries
- 4
01
Overview
Phase 2, open-label trial of drisapersen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by BioMarin Pharmaceutical. Primary endpoints: Efficacy of PRO044 at 48 weeks and Treatment-emergent adverse events at 48 weeks. Started Dec 2014; status: terminated.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02329769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329769.